Total trials
506
Active
108
Phase 3
10
Total enrollment
11,445,326
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Metformin | — | — | — | — | — | 1 | |
| Ursodeoxycholic Acid | — | — | — | — | — | 1 | |
| Encapsulated FMT | — | — | — | — | — | 1 | |
| Empagliflozin 10mg OD | — | — | — | — | — | 1 | |
| Mirtazapine | — | — | — | — | — | 1 | |
| Levetiracetam | — | — | — | — | 2 | ||
| THC | — | — | — | — | — | 2 | |
| CBD | — | — | — | — | — | 2 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Blood Product | — | — | — | — | — | 1 | |
| delta-9-tetrahydrocannabinol | — | — | — | — | — | 1 | |
| Diroximel fumarate | — | — | — | — | — | 1 | |
| Minocycline 200mg | — | — | — | — | — | 1 | |
| THC + CBD | — | — | — | — | — | 1 | |
| Methotrexate | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 |
Next readouts
- 2024-12-31
- 2025-12-01
- 2026-02
- 2026-04
- 2026-05
- 2026-12
- 2027-01-20
- 2027-09-01
- 2027-12-31
- 2028-01-31
Top conditions
- Anxiety19
- Depression17
- Healthy16
- Psychosis14
- Schizophrenia10
- Major Depressive Disorder9
- Autism Spectrum Disorder8
- Heart Failure8
Frequently asked questions about King's College London
- How many clinical trials does King's College London have on ClinicalTrials.gov?
- King's College London is listed as the lead sponsor on 506 clinical trials in ClinicalTrials.gov, 108 of which are currently active (recruiting, enrolling, or ongoing).
- How many of King's College London's trials are in Phase 3?
- 10 of King's College London's trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does King's College London focus on?
- King's College London's most-studied conditions on ClinicalTrials.gov are Anxiety, Depression, Healthy, Psychosis, Schizophrenia.
- When are King's College London's next clinical trial readouts?
- King's College London has 10 upcoming primary-completion readouts tracked here; the soonest is “Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus”, expected around 2024-12-31.